Status:
UNKNOWN
Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions:
Hereditary Breast and Ovarian Cancer
Eligibility:
FEMALE
30-49 years
Brief Summary
1. Premenopausal BRCA1 / 2 or PALB2 gene mutation carriers who receive hormone replacement therapy (HRT) after preventive salpingo-oophorectomy (PBSO) have a better quality of sexual, psychological, c...
Eligibility Criteria
Inclusion
- Age between 30 and 49 years
- Being a member of a family with a history of hereditary breast and ovarian cancer, with a cancer risk\> 10% or being a carrier of the BRCA1 / 2 or PALB2 mutation.
Exclusion
- Personal history of oophorectomy for benign or malignant ovarian pathology.
- Personal history of breast cancer.
Key Trial Info
Start Date :
March 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05409222
Start Date
March 12 2020
End Date
October 1 2023
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041